361 related articles for article (PubMed ID: 24429402)
1. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
2. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
3. AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
Chow BSM; Kocan M; Shen M; Wang Y; Han L; Chew JY; Wang C; Bosnyak S; Mirabito-Colafella KM; Barsha G; Wigg B; Johnstone EKM; Hossain MA; Pfleger KDG; Denton KM; Widdop RE; Summers RJ; Bathgate RAD; Hewitson TD; Samuel CS
J Am Soc Nephrol; 2019 Nov; 30(11):2191-2207. PubMed ID: 31511361
[TBL] [Abstract][Full Text] [Related]
4. New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.
Sasser JM
Kidney Int; 2014 Jul; 86(1):9-10. PubMed ID: 24978374
[TBL] [Abstract][Full Text] [Related]
5. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
Chow BS; Chew EG; Zhao C; Bathgate RA; Hewitson TD; Samuel CS
PLoS One; 2012; 7(8):e42714. PubMed ID: 22936987
[TBL] [Abstract][Full Text] [Related]
6. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
Mookerjee I; Hewitson TD; Halls ML; Summers RJ; Mathai ML; Bathgate RA; Tregear GW; Samuel CS
FASEB J; 2009 Apr; 23(4):1219-29. PubMed ID: 19073841
[TBL] [Abstract][Full Text] [Related]
7. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.
Heeg MH; Koziolek MJ; Vasko R; Schaefer L; Sharma K; Müller GA; Strutz F
Kidney Int; 2005 Jul; 68(1):96-109. PubMed ID: 15954899
[TBL] [Abstract][Full Text] [Related]
8. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.
Hossain MA; Man BC; Zhao C; Xu Q; Du XJ; Wade JD; Samuel CS
Biochemistry; 2011 Mar; 50(8):1368-75. PubMed ID: 21229994
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
Sasser JM
Am J Physiol Regul Integr Comp Physiol; 2013 Sep; 305(6):R559-65. PubMed ID: 23883673
[TBL] [Abstract][Full Text] [Related]
10. Mesangial cells cultured from pregnant rats display reduced reactivity to angiotensin II: the role of relaxin, nitric oxide and AT2 receptor.
Carvalho LN; Cristovam PC; Passos CS; Boim MA
Cell Physiol Biochem; 2012; 30(6):1456-64. PubMed ID: 23207895
[TBL] [Abstract][Full Text] [Related]
11. Reduced sensitivity of the renal vasculature to angiotensin II in young rats: the role of the angiotensin type 2 receptor.
Brown RD; Hilliard LM; Mirabito KM; Wirth LC; Moritz KM; Evans RG; Denton KM
Pediatr Res; 2014 Nov; 76(5):448-52. PubMed ID: 25119338
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II Type 2 Receptor and Receptor Mas Are Colocalized and Functionally Interdependent in Obese Zucker Rat Kidney.
Patel SN; Ali Q; Samuel P; Steckelings UM; Hussain T
Hypertension; 2017 Oct; 70(4):831-838. PubMed ID: 28827476
[TBL] [Abstract][Full Text] [Related]
13. Role of Mas receptor antagonist (A779) on pressure diuresis and natriuresis and renal blood flow in the absence of angiotensin II receptors type 1 and 2 in female and male rats.
Mansoori A; Oryan S; Nematbakhsh M
J Physiol Pharmacol; 2014 Oct; 65(5):633-9. PubMed ID: 25371522
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II Type 2 Receptor Decreases Transforming Growth Factor-β Type II Receptor Expression and Function in Human Renal Proximal Tubule Cells.
Guo HL; Liao XH; Liu Q; Zhang L
PLoS One; 2016; 11(2):e0148696. PubMed ID: 26867007
[TBL] [Abstract][Full Text] [Related]
16. Relaxin Attenuates Organ Fibrosis
Barsha G; Walton SL; Kwok E; Mirabito Colafella KM; Pinar AA; Hilliard Krause LM; Gaspari TA; Widdop RE; Samuel CS; Denton KM
Kidney360; 2021 Nov; 2(11):1781-1792. PubMed ID: 35373008
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis.
Ding H; Jiang L; Xu J; Bai F; Zhou Y; Yuan Q; Luo J; Zen K; Yang J
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F561-F575. PubMed ID: 28228400
[TBL] [Abstract][Full Text] [Related]
18. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists.
Hu X; Myhr C; Huang Z; Xiao J; Barnaeva E; Ho BA; Agoulnik IU; Ferrer M; Marugan JJ; Southall N; Agoulnik AI
Biochemistry; 2016 Mar; 55(12):1772-83. PubMed ID: 26866459
[TBL] [Abstract][Full Text] [Related]
19. Chronic blockade of the AT2 receptor with PD123319 impairs insulin signaling in C57BL/6 mice.
Muñoz MC; Burghi V; Miquet JG; Cervino IA; Quiroga DT; Mazziotta L; Dominici FP
Peptides; 2017 Feb; 88():37-45. PubMed ID: 27979738
[TBL] [Abstract][Full Text] [Related]
20. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
